Myocrisin

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Buy It Now

Active ingredient:

Sodium aurothiomalate

Patient Information leaflet

                                MYOCRISIN(R)
1
MYOCRISIN(R)
_Sodium aurothiomalate_
CONSUMER MEDICINE INFORMATION (CMI)
WHAT IS IN THIS LEAFLET
This leaflet answers some common
questions about Myocrisin.
It does not contain all the available
information. It does not take the
place of talking to your doctor or
pharmacist.
All medicines have risks and
benefits. Your doctor has weighed
the risks of you being given this
medicine against the benefits they
expect it will have for you.
IF YOU HAVE ANY CONCERNS ABOUT
BEING GIVEN THIS MEDICINE, ASK YOUR
DOCTOR OR PHARMACIST.
KEEP THIS LEAFLET WITH THE MEDICINE.
You may need to read it again.
WHAT MYOCRISIN IS USED
FOR
Myocrisin is a type of medicine used
to help treat rheumatoid arthritis and
Still's disease (a form of arthritis in
children).
Myocrisin helps to reduce the
inflammation which can occur with
arthritis.
Your doctor, however, may prescribe
Myocrisin for another purpose.
ASK YOUR DOCTOR OR PHARMACIST IF
YOU HAVE ANY QUESTIONS ABOUT WHY
IT HAS BEEN PRESCRIBED FOR YOU.
This medicine is only available with
a doctor's prescription.
BEFORE YOU ARE GIVEN IT
_WHEN YOU MUST NOT BE GIVEN_
_IT_
DO NOT RECEIVE MYOCRISIN IF YOU
HAVE:
*
LIVER DISEASE
*
KIDNEY DISEASE
*
DIABETES
*
BLOOD DISORDERS OR A HISTORY OF
BLOOD DISORDERS
*
ANY SERIOUS SKIN DISORDERS
*
ARE PREGNANT OR PLAN TO BECOME
PREGNANT
DO NOT RECEIVE MYOCRISIN IF YOU ARE
ALLERGIC TO IT OR ANY OF THE
INGREDIENTS LISTED AT THE END OF THIS
LEAFLET.
Some symptoms of an allergic
reaction include skin rash, itching,
shortness of breath or swelling of the
face, lips or tongue, which may cause
difficulty in swallowing or
breathing.
DO NOT USE MYOCRISIN IF THE
SOLUTION HAS DARKENED IN COLOUR.
Any solution darker than a pale
yellow should not be used.
DO NOT RECEIVE IT IF YOU ARE
PREGNANT OR INTEND TO BECOME
PREGNANT.
It may affect your developing baby if
you are given it during pregnancy.
DO NOT RECEIVE IT IF YOU ARE
BREASTFEEDING O
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                 
_Myocrisin PI _
_ _
_#7557v4.0 Page _
1_ _
 
PRODUCT INFORMATION 
MYOCRISIN
®
NAME OF THE MEDICINE 
NON-PROPRIETARY NAME 
Sodium aurothiomalate 
DESCRIPTION 
Each ampoule of MYOCRISIN solution for injection contains 10mg, 20mg
or 50mg of sodium 
aurothiomalate and phenylmercuric nitrate and water for injections. 
PHARMACOLOGY 
SITE AND MODE OF ACTION 
In rheumatoid arthritis, MYOCRISIN appears to suppress the disease
processes in two ways.  
Firstly it penetrates into the joint cavity and affects the lysosomal
membranes.  Secondly, it binds 
to plasma proteins, including IgG, the rheumatoid factor and the
immune complex so that when the 
lysosomes ingest immune complex the gold is absorbed with it and
inactivates lysosomal enzymes 
within the cell. 
INDICATIONS 
Adjunctive treatment of rheumatoid arthritis that is not
adequately controlled by other anti-
inflammatory agents and conservative measures.  In chronic,
advanced cases of rheumatoid 
arthritis, gold therapy is less valuable. 
Still's disease. 
CONTRAINDICATIONS 
Hypersensitivity to any component of this product.  Patients with
gross renal or hepatic disease, 
diabetes, marked toxaemia, a history of blood dyscrasias or
exfoliative dermatitis. 
Use in Pregnancy is contraindicated (See Precautions). 
PRECAUTIONS 
Every candidate for gold therapy should be investigated fully to
prevent the administration of gold 
to those with gross renal or hepatic defects, diabetes, marked
toxaemia, a history of blood 
dyscrasias or dermatitis.  Before starting treatment, and again
before each injection, the urine 
should be tested for protein, the skin inspected for rashes, and
a full blood count performed, with a 
numerical platelet count (not an estimation).  The availability,
whenever possible, of the results of 
blood counts before the next injection is a useful aid in minimising
toxic reactions.  Minimum values 
below which gold should not be given until the count has been repeated
and there is r
                                
                                Read the complete document
                                
                            

Search alerts related to this product

View documents history